NEW YORK, NY / ACCESSWIRE / March 2, 2017 / U.S. markets skyrocketed to record highs Wednesday as President Trump's speech to Congress provided an optimistic view for the U.S. economy and as Federal Reserve officials hinted at an interest rate hike. The Dow Jones Industrial Average surged 303.31 points, 1.46 percent to close at 21,115.55, surpassing the 21,000 level for the first time in history. The S&P 500 gained 1.37 percent to close at 2,395.96. The 1,000 point increase took 24 trading sessions, tying the record for fastest 1,000 point increase in history.

Register today for a free membership and gain access to daily research reports at: RDInvesting.com

"My economic team is developing historic tax reform that will reduce the tax rate on our companies so they can compete and thrive anywhere and with anyone. At the same time, we will provide massive tax relief for the middle class," said President Trump in his speech to congress on February 28th. "We must create a level playing field for American companies and workers."

"The market woke up this morning believing in Trump's ability to enact a pro-business agenda," said Tom Wright, director of equities at JMP Securities. "The trend has been up, because of underlying optimism, but it's been tempered by concern they may not be able to get that agenda through Congress."

Let's Take a Closer Look at Today's Trending Tickers

Clean Energy Fuels' shares spiked 16.73 percent to close at $2.86 a share on Wednesday. The stock traded between $2.67 and $3.12 on volume of 9.94 million shares traded. The company has announced that BP p.l.c. has agreed to acquire the upstream portion of Clean Energy's renewable natural gas business and sign a long-term supply contract with Clean Energy. "Under terms of the agreement, BP will pay $155 million for Clean Energy's existing biomethane production facilities, its share of two new facilities and its existing third party supply contracts for renewable natural gas." Clean Energy said in its news release.

"We started our Redeem fueling business from scratch less than four years ago and have grown it into a significant enterprise," said Andrew Littlefair, Clean Energy's president and chief executive officer. "This transaction will help to take it to the next level. BP's investment in and focus on renewable natural gas supply will ensure that Clean Energy can meet the growing demand of our customers for low carbon, renewable fuel."

Access Today's Clean Energy Fuels Research Report Click Here

Amicus Therapeutics' shares jumped 17.10 percent to close at $7.60 a share on Wednesday. The stock traded between $6.83 and $7.79 on volume 12.25 million shares traded. The Biotech Industry received a boost Wednesday as President Trump called the U.S. Food and Drug Administration's drug approval process "slow and burdensome". In his speech to congress on Tuesday, President Trump specifically talked about Amicus Therapeutics' CEO John Crowley's daughter, Megan Crowley.

"An incredible young woman is with us this evening who should serve as an inspiration to us all. Today is Rare Disease day, and joining us in the gallery is a Rare Disease Survivor, Megan Crowley. Megan was diagnosed with Pompe Disease, a rare and serious illness, when she was 15 months old. She was not expected to live past 5. On receiving this news, Megan's dad, John, fought with everything he had to save the life of his precious child. He founded a company to look for a cure, and helped develop the drug that saved Megan's life. Today she is 20 years old -- and a sophomore at Notre Dame," said President Trump.

Access Today's Amicus Therapeutics Research Report Click Here

Today's Features Includes:

Clean Energy Fuels Corp. (NASDAQ: CLNE)

Amicus Therapeutics, Inc. (NASDAQ: FOLD)

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com